https://www.selleckchem.com/products/zn-c3.html
168% and 21.529%). The pooled odd ratios comparing D-MMR to proficient MMR favored low-stage EC disease (1.565; 0.894 to 2.74, lymphovascular invasion (1.765; 1.293 to 2.409), and myometrial invasion 50% (1.271; 0.871 to 1.853). Almost one-quarter of EC patients present with D-MMR tumors. The majority has less aggressive endometrioid histology. D-MMR presents at lower tumor stages compared to MMR-proficient cases in EC. However other metastatic parameters are comparatively higher in the D-MMR disease setting. Almost one-quarter of E
Like
Comment
Share
